Wavefront-guided LASIK: a safe treatment for myopia & astigmatism

Article

Wavefront-guided LASIK is a safe and efficacious way to correct moderate to high myopia and compound myopic astigmatism.

Wavefront-guided LASIK is a safe and efficacious way to correct moderate to high myopia and compound myopic astigmatism, according to a study published in the January issue of the Journal of Cataract and Refractive Surgery.

Simon R. Bababeygya and co-workers from Stanford University School of Medicine, Stanford, California, USA conducted a retrospective study which included 89 eyes of 45 patients with moderate (-6.0 to -8.0 D) and high (>-8.00 D) myopia treated with wavefront-guided LASIK using the WaveScan linked to the CustomVue system (AMO). All eyes were analyzed preoperatively and one, three, and 12 months postoperatively.

Mean age was 38.4 years ±7.14 (SD) and no eye was retreated during the study. The mean manifest refraction spherical equivalent was -8.10±0.98 D (range -6.00 to -10.63 D) preoperatively and -0.33±0.55 D (range -1.625 to 1.375 D) 12 months postoperatively. Ninety percent of the eyes were within ±1.00 D of the intended correction and 64% were within ±0.50 D. For all eyes, the safety index was 1.00 and the efficacy index, 1.18.

The results of the study confirm that the correction of moderate to high myopia and compound myopic astigmatism using wavefront-guided LASIK is both safe and effective.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.